Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (15348)	11/11/1998 5:54:00 PM
From: poodle	Read Replies (2) \| Respond to of 18691

"OXGN, Another Geron?" They are pretending to be rather another ENMD, but scale ... No, whatever you say, market is becoming more and more rational. You see, trial initiated, plus fresh news from 1997 and stock only doubled. (g) From PR: "In one such study, published in Cancer Research, v. 57:1829 (May 1997) researchers found that a single dose of Combretastatin reduced tumor blood flow in MICE by 93 percent. Twenty-four hours after injection with Combretastatin, 95 percent of the cancer cells were dead as a result of being deprived of oxygen and nutrients."